Selecting & Optimizing Predictive & Cost-Effective Models to Enhance Target Selection, Facilitate Biomarker Discovery & Achieve Clinical Translatability
2026 is set to reshape the future of preclinical oncology.
As we close out 2025 with the UK accelerating its roadmap to phase out animal testing and SillaJen securing a landmark FDA approval using only organoid efficacy data, the momentum has never been stronger. With immunomodulating therapies surging and preclinical development costs continuing to climb, the pressure is on for biopharma to cut attrition and de-risk every preclinical decision. The message is clear: investing in more trustworthy, physiologically relevant, and cost-effective models is now mission‑critical for successfully advancing assets worldwide.
The combination of relatively small size, yet high quality of the program was very enjoyable. Heavily focused on therapeutics. I learnt a lot.
Principal Scientist, Sprint Biosciences
Chance to interact with Nordic-based research and CRO teams in the field of tumour models. Adequate time to meet with speakers and attendees. New results of research in immuno-oncology were presented.
Chief Scientific Officer, BlueWave Therapeutics
Interesting talks covering a broad variety of tumour models.
Senior Scientist, NEOGAP Therapeutics
Explore the Full Event Guide
- Free* to attend for biotech & pharma
- 70+ tumour modelling experts from biopharma based in the Nordics, Poland, Czechia, Germany, Austria and Switzerland
- Dedicated networking with decision-makers through roundtables, panels, and structured networking sessions
- Data-driven drug developer case studies on in vitro, complex in vitro, in vivo & more across multiple indications & modalities including ADCs, bispecifics, vaccines, cell therapy, and small molecules
- The only meeting in the Nordics uniting biotech, pharma, and model providers to master cutting‑edge tumour modelling, sharpen vendor selection, and confidently de‑risk preclinical assets
Speakers
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest preclinical and translational data on tumour modelling, and gain first-hand insight into innovations on modelling for in vitro, in vivo, complex in vitro and more across multiple modalities.
Partner With Us
Position yourself as the partner of choice amongst leading model developers and solution providers to ensure your brand is at the heart of biopharma deals and collaborations.
Join Nordic Oncology Industry Experts
Connect with preclinical, translational, discovery, pharmacology, and biology drug developers from the leading Nordic biopharma companies through focused presentations, panels, and networking designed to spark meaningful scientific and commercial conversations.